Production (Stage)
Carisma Therapeutics, Inc.
CARM
$0.4297
-$0.0219-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.08% | 7.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.08% | 7.92% | |||
| Cost of Revenue | -41.22% | 37.54% | |||
| Gross Profit | 54.49% | -50.17% | |||
| SG&A Expenses | -0.59% | -24.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.04% | 18.02% | |||
| Operating Income | 41.13% | -20.63% | |||
| Income Before Tax | 47.46% | -38.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.46% | -38.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.46% | -38.84% | |||
| EBIT | 41.13% | -20.63% | |||
| EBITDA | 42.89% | -22.40% | |||
| EPS Basic | 47.49% | -38.31% | |||
| Normalized Basic EPS | 40.77% | -22.58% | |||
| EPS Diluted | 47.49% | -38.31% | |||
| Normalized Diluted EPS | 40.77% | -22.58% | |||
| Average Basic Shares Outstanding | 0.05% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||